Vaccines and Vaccinations for Adults
Springer International Publishing (Verlag)
978-3-032-04019-0 (ISBN)
This textbook provides a comprehensive reference on adult vaccines and immunization practices tailored to the European context. The reader is guided from assessing the health burden of vaccine-preventable infections to evaluating the cost-effectiveness of new adult vaccination schedules, introducing and establishing such initiatives, and communicating and managing vaccination programs. The authors update on routine and new vaccines for a number of common pathogens in Europe, such as SARS-CoV-2, RSV and influenza, and also provide information on travel-related vaccinations. The book discusses in detail individualized, risk-based vaccination for different patient groups and also provides insights into current pipeline development, and an outlook on the future prospects for adult vaccination.
All editors are part of the Adult Immunization Board (AIB) created in November 2022. The AIB is a European platform that brings together experts to address key challenges in adult vaccination. The goal is to promote evidence-based policies, knowledge sharing, and cross-country collaboration to improve adult immunization. The AIB secretariat based at the University of Antwerp and University of Florence is responsible for the operational and scientific tasks of the AIB and took the lead in coordinating the writing of this book supported by its AIB advisors and other selected experts.
Prof. Dr. Pierre Van Damme obtained his Medical Degree from the University of Antwerp in 1984 and has been active in vaccine, clinical trial and infectious disease research for more than 35 years. He conducted more than 550 national and international vaccine studies with vaccines against various pathogens. Since 2000 he is full professor in Vaccinology at the University of Antwerp, Faculty of Medicine and Health Sciences, and teaches vaccinology in national and international courses. Pierre Van Damme is director of the Centre for the Evaluation of Vaccination (CEV, University of Antwerp), which he founded in 1994. The CEV is a WHO Collaborating Centre for the WHO European Region for the control and prevention of infectious diseases. In 2022, together with Prof Arnaud Marchant, Pierre Van Damme set up the European Plotkin Institute for Vaccinology, including Vaccinopolis, an innovative vaccine research centre to accelerate the evaluation of vaccines for pandemic and endemic pathogens. Pierre Van Damme has been for more than 25 years a regular advisor for national and international organizations, including the National Immunization Technical Advisory Group, and the World Health Organization (European Regional Office and Headquarters). He has been appointed as chairman of the European Technical Advisory Group of Experts on communicable diseases and vaccines for the WHO European Region (ETAGE) (2005-2015). Pierre Van Damme obtained several awards: the Research Award of the University of Antwerp, the Belgian Social Medicine Award Jean Van Beneden for his work on the introduction of universal hepatitis B immunization programs; the prestigious Bill Marshall award of the ESPID society (2014); the ACRP (Association of Clinical Research Professionals) with the European Outstanding Leadership Award (2017); the prestigious Paul Harris Fellowship by the Rotary Foundation 2017); the Balmis distinction Award (Almeria, Spain, 2017), the AHA Antwerp Innovation award (2019), the science communication award UAntwerpen (2021), and recently the International Vaccine Institute-SK Bioscience Park Mahnhoon Award (Korea, 2025). Pierre Van Damme is member of the Belgian Royal Academy of Medicine.
Prof. Dr. Paolo Bonanni is a Full Professor Hygiene and Public Health at the Faculty of Medicine and director of the department of Health Sciences at the University of Florence, Italy. Professor Bonanni graduated in Medicine and Surgery (MD) in 1985 and obtained two specialisations in Hygiene and Preventive Medicine at the University of Genoa, Italy. Professor Bonanni s scientific activity covered the epidemiology and prevention of infectious diseases, especially viral hepatitis, diphtheria, tetanus, pertussis, influenza, measles, rubella, varicella, and, more recently, bacterial invasive diseases and human papillomavirus, including clinical trials and economic evaluation of vaccination strategies. Professor Bonanni has been a member of the National Vaccination Commission of the Italian Ministry of Health, and he acts as an expert advisor for the European Centre for Disease Prevention and Control (ECDC) based in Stockholm, Sweden. He has been appointed member of the European Technical Advisory Group of Experts on communicable diseases and vaccines for the WHO European Region (ETAGE) (2012-2017). He is standing adviser of the Viral Hepatitis Prevention Board (VHPB) and HPV Prevention and Control Board. Paolo Bonanni received several grants from the Italian Ministry of Health on projects regarding vaccine-preventable infections and was/is responsible for 5 EU-funded projects on vaccination (ANTRES, EURO-HEPNET, VACSATC, HEPSCREEN, DRIVE). Paolo Bonanni is member of the Steering Committee of the International Council on Adult Immunization (ICA), Johns Hopkins Univer
Part I: General Aspects of Vaccines And Vaccination for Adults.- Chapter 1. Introduction on Adult Caccination.- Chapter 2. Overview of Licensed Vaccines for Adults in Europe.- Chapter 3. Understanding the Concepts of Vaccine Immunology, Efficacy And Effectiveness.- Chapter 4. The Current Status and Evolution of Vaccination Programs for Adults in Europe.- Chapter 5. Strategies for Introducing and Implementing Vaccines for Adults into National Immunization Programmes in Europe.- Chapter 6. Economic Evaluations of Vaccines for Adults and Programs in Europe.- Chapter 7. Confidence in Adult Vaccination in Europe: Challenges and Solutions.- Chapter 8. Pharmacovigilance of Vaccines.- Chapter 9. Adult Vaccination Policy in Europe: Governance and Key Stakeholders.- Chapter 10. Vaccines Manufacturing Process.- Part II: Routine Vaccines and Vaccinations For Adults.- Chapter 11. COVID-19 and SARS-CoV-2 Vaccines in European Adults.- Chapter 12. Herpes Zoster Vaccination.- Chapter 13. Seasonal Influenza Vaccination.- Chapter 14. Pneumococcal Vaccination .- Chapter 15. Respiratory Syncytial Virus Vaccination.- Chapter 16. TBE vaccination.- Chapter 17. Tetanus, Diphtheria, And Pertussis Vaccination In Adults.- Part III: Catch-up Vaccines And Vaccinations for Adults.- Chapter 18. Catching up Child and Adolescent Vaccinations in Adults.- Chapter 19. Vaccination of Pregnant Women.- chapter 20. Vaccination of Immunocompromised Subjects.- Chapter 21. Mpox and Vaccination: Lessons from Outbreaks.- Chapter 22. Adult vaccines for Travel Outside Europe.- Chapter 23. Adult Vaccines For Occupational Activities.- Part V: Future perspective for Vaccines and Vaccinations for Adults.- Chapter 24. New Vaccines for Adults In Research And Development.
| Erscheinungsdatum | 15.11.2025 |
|---|---|
| Zusatzinfo | XIV, 285 p. 31 illus., 28 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 178 x 254 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Mikrobiologie / Infektologie / Reisemedizin |
| Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie | |
| Schlagworte | COVID-19 vaccine • Dengue Vaccine • disease prevention • Ebola Vaccine • healthy ageing • Life-long Immunity • Risk Patient Groups • travel vaccines • vaccination program • Vaccine Administration • Vaccine development |
| ISBN-10 | 3-032-04019-1 / 3032040191 |
| ISBN-13 | 978-3-032-04019-0 / 9783032040190 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
